Avidity

Novartis Stands by Avidity Deal After $1.9 Billion Del-desiran Setback

Novartis is absorbing a steep charge after the failure of del-desiran, but management is signaling that the setback does not alter its confidence in the broader Avidity transaction. The company also lifted its annual profit guidance, underscoring a message of operational resilience even as clinical-trial volatility weighs on near-term earnings. Investors are now weighing whether Novartis can keep executing its pipeline strategy while defending the long-term case for external innovation.